Affimed对复发的Hodgkin淋巴瘤的治疗显示,在第二阶段试验中,答复率为86%。 Affimed's treatment for relapsed Hodgkin lymphoma shows an 86% response rate in a phase 2 trial.

Affimed报告说,一项将Acimtamig与AlloNK合为一体的研究取得了积极的成果,该研究旨在治疗复发/后患古典Hodgkin淋巴瘤(R/R CHL)的病人。 Affimed has reported positive results from a study combining acimtamig with AlloNK® to treat patients with relapsed/refractory classical Hodgkin lymphoma (R/R cHL). 治疗显示,在接受重症治疗的22名患者中,总体反应率为86%,完全反应率为55%。 The treatment showed an overall response rate of 86% and a complete response rate of 55% in 22 heavily treated patients. 这项研究是LuminICE-203第2阶段试验的一部分,也表明安全情况管理良好,没有出乎意料的问题。 The study, part of the LuminICE-203 phase 2 trial, also indicated a well-managed safety profile with no unexpected issues.